{
    "clinical_study": {
        "@rank": "85591", 
        "acronym": "DASAPOST", 
        "arm_group": {
            "arm_group_label": "Dasatinib (Sprycel)", 
            "arm_group_type": "Experimental", 
            "description": "Dasatinib (Sprycel): 100 mg QD administered orally as continuous daily dosing (CDD)until disease progression or adverse events that, by protocol definition or Investigator judgment, would preclude further treatment with dasatinib"
        }, 
        "brief_summary": {
            "textblock": "Trial try to assess the efficacy of dasatinib in terms of major molecular response rate at 6\n      months in patients with CP-CML who have achieved complete cytogenetic response without major\n      molecular response after at least 18 months on Imatinib 400/600."
        }, 
        "brief_title": "Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a single-arm, open-label, phase II trial for patients in complete cytogenetic\n      response that have not achieved major molecular response or have lost a prior major\n      molecular response, after at least 18 months of treatment with imatinib.\n\n      All enrolled patients will receive dasatinib 100 mg once daily orally for 1 year until\n      progression, loss of cytogenetic response, transformation to advanced phases, unacceptable\n      toxicity (clinical adverse event, lab abnormality or concurrent disease), pregnancy if a\n      female or withdrawal of consent, whichever happens first. Patients will undergo BCR-ABL\n      assessments at study entry and every 3 months (central lab) and immunophenotyping and\n      studies for clonal lymphocytosis at study entry, at 3 and 6 months.\n\n      Cytogenetic assessment will be done only if loss of response/progression/clonal evolution\n      are suspected.\n\n      Subjects will be evaluated for the efficacy and safety of dasatinib (Sprycel). Lymphocytosis\n      data will be collected for all patients and separate description for efficacy and safety\n      parameters will be done in patients with and without lymphocytosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients >or = 18 years\n\n          -  Diagnostic of Ph+ Chronic Myeloid Leukemia in first chronic phase\n\n          -  Treated with Imatinib 400 mg per day or 600 mg per day for at least 18 months. A wash\n             out period of at least 7 days for imatinib is required prior to dasatinib\n             administration\n\n          -  Patients meet criteria of late suboptimal response (complete cytogenetic response\n             with no major molecular response) or have lost major molecular response\n\n          -  Ability to understand and voluntarily sign the informed consent for\n\n          -  Women of childbearing potential (WOCBP) must be using an adequate method of\n             contraception to avoid pregnancy and have a negative pregnancy test, a maximum of 72\n             hours prior to study drug start.\n\n        Sexually active men must also use effective contraceptive methods during the treatment.\n\n          -  Women must not be breastfeeding\n\n        Exclusion Criteria:\n\n          -  Patients treated with Imatinib at a dose different of 400/600 mg per day\n\n          -  Patients treated with other TKI than imatinib\n\n          -  Loss of cytogenetic response at study entry\n\n          -  ECOG \u2265 3\n\n          -  Inadequate bone marrow reserve: ANC <1.5 x 109/L and/or Platelet count < 100 x 109/L\n\n          -  Inadequate hepatic function (Alanine aminotransferase (ALT) and/or aspartate\n             aminotransferase (AST)> 2.5 X institutional upper limit of normal (IULN). Total\n             bilirubin > 1.5 X IULN (unless Gilbert syndrome has been diagnosed)\n\n          -  Inadequate renal function (serum Cr >3 UNL or ClCr <45 ml/min)\n\n          -  Patients receiving concurrent treatment with other experimental drugs or anti-cancer\n             therapy\n\n          -  Patients with uncontrolled concurrent disease:\n\n        Known pleural effusion at baseline Clinically-significant gastrointestinal disease or\n        surgery that would compromise absorption of study drug (eg, uncontrolled nausea or\n        malabsorption syndrome) Clinically-significant known coagulation or platelet function\n        disorder (not related to thrombocytopenia), eg, von Willebrand's disease Other active\n        malignancy requiring concurrent intervention\n\n        Uncontrolled or significant cardiovascular disease, including any of the following:\n\n        Myocardial infarction within 6 months of enrolment date Uncontrolled angina or congestive\n        heart failure within 3 months of enrolment date Left ventricular ejection fraction (LVEF)\n        < 40% Significant cardiac conduction abnormality, including history of\n        clinically-significant ventricular arrhythmia (such as ventricular tachycardia,\n        ventricular fibrillation, or Torsades de Pointes), history of third degree heart block or\n        diagnosed congenital long QT syndrome, and/or prolonged QTc/f interval > 450 msec on\n        baseline ECG.\n\n          -  Patients with active or uncontrolled infections or with serious illnesses or medical\n             conditions that would not permit the patient to be managed according to the protocol.\n\n          -  Patients unable or unwilling to give written, informed consent prior to study\n             participation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802450", 
            "org_study_id": "DASAPOST"
        }, 
        "intervention": {
            "arm_group_label": "Dasatinib (Sprycel)", 
            "intervention_name": "Dasatinib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dasatinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 19, 2013", 
        "link": [
            {
                "description": "Dynamic Solutions CRO", 
                "url": "http://www.dynasolutions.com"
            }, 
            {
                "description": "Bristol Myers Squibb", 
                "url": "http://www.bms.es"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "ernesto.perezpersona@osakidetza.net", 
                    "last_name": "P\u00e9rez Ernesto, Dr", 
                    "phone": "34 945 00 71 30"
                }, 
                "facility": {
                    "address": {
                        "city": "Vitoria", 
                        "country": "Spain", 
                        "state": "Alava", 
                        "zip": "01010"
                    }, 
                    "name": "Hospital Txagorritxu"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "apayer.angel@gmail.com", 
                    "last_name": "Ram\u00edrez Angel, Dr", 
                    "phone": "985108000", 
                    "phone_ext": "38345"
                }, 
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "state": "Asturias", 
                        "zip": "33006"
                    }, 
                    "name": "Hospital Universitario Central de Asturias"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "30566bxc@comb.cat", 
                    "last_name": "Xicoy Blanca, Dr", 
                    "phone": "34 934 651 200"
                }, 
                "facility": {
                    "address": {
                        "city": "Badalona", 
                        "country": "Spain", 
                        "state": "Barcelona"
                    }, 
                    "name": "Hospital Germans Trias i Pujol"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fcasadom@sescam.jccm.es", 
                    "last_name": "Casado Luis Felipe, Dr", 
                    "phone": "34 925 269 200", 
                    "phone_ext": "49243"
                }, 
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "Spain", 
                        "state": "Castilla La Mancha", 
                        "zip": "45004"
                    }, 
                    "name": "Complejo Hospitalario de Toledo - Hospital Virgen de la Salud"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "manuel.mateo.perez.encinas@sergas.es", 
                    "last_name": "Mateo Manuel, Dr", 
                    "phone": "34 981 95 14 53"
                }, 
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "state": "La Coru\u00f1a", 
                        "zip": "15706"
                    }, 
                    "name": "Complejo Hospitalario Universitario de Santiago"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mmhermosilla@riojasalud.es", 
                    "last_name": "Hermosilla M\u00aa del Mar, Dr", 
                    "phone": "34 941 298 000", 
                    "phone_ext": "81891"
                }, 
                "facility": {
                    "address": {
                        "city": "Logro\u00f1o", 
                        "country": "Spain", 
                        "state": "La Rioja", 
                        "zip": "26006"
                    }, 
                    "name": "Hospital San Pedro de La Rioja"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cesar.soto@hotmail.es", 
                    "last_name": "Soto C\u00e9sar, Dr", 
                    "phone": "34 986413144", 
                    "phone_ext": "1026"
                }, 
                "facility": {
                    "address": {
                        "city": "Vigo", 
                        "country": "Spain", 
                        "state": "Pontevedra", 
                        "zip": "36211"
                    }, 
                    "name": "Hospital POVISA"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "c.boque@iconcologia.net", 
                    "last_name": "Boqu\u00e9 Concepci\u00f3n, Dr", 
                    "phone": "932607796", 
                    "phone_ext": "3037"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08907"
                    }, 
                    "name": "Institut Catal\u00e1 d'Oncologia L'Hospitallet"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ndelasheras22@hotmail.com", 
                    "last_name": "de las Heras Natalia, Dr", 
                    "phone": "34 987 23 74 00", 
                    "phone_ext": "43319"
                }, 
                "facility": {
                    "address": {
                        "city": "Le\u00f3n", 
                        "country": "Spain", 
                        "zip": "24071"
                    }, 
                    "name": "Hospital de Le\u00f3n"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jvgarciag.hrc@salud.madrid.org", 
                    "last_name": "Garc\u00eda Guti\u00e9rrez Valent\u00edn, Dr", 
                    "phone": "34 91 336 8686"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Universitario Ram\u00f3n y Cajal"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rosam.ayala@salud.madrid.org", 
                    "last_name": "Ayala Rosa, Dr", 
                    "phone": "34 91 779 27 88"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital 12 de Octubre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "depazraquel@gmail.com", 
                    "last_name": "de Paz Raquel, Dr", 
                    "phone": "34 917277116"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }, 
                    "name": "Hospital Universitario La Paz"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jlsteegmann@gmail.com", 
                    "last_name": "Steegmann Juan Luis, Dr", 
                    "phone": "34 91 520 23 16"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28006"
                    }, 
                    "name": "Hospital Universitario de la Princesa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ferminsg@usal.es", 
                    "last_name": "S\u00e1nchez Ferm\u00edn, Dr", 
                    "phone": "923 29 11 00", 
                    "phone_ext": "55750"
                }, 
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain", 
                        "zip": "37007"
                    }, 
                    "name": "Hospital Universitario de Salamanca"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gallaraviles.raquel@gmail.com", 
                    "last_name": "Montero Isabel, Dr", 
                    "phone": "34 955013273"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "Hospital Virgen del Roc\u00edo"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicenter, Open-label, Non-randomized Phase II Trial of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Who Meet Criteria for Late Suboptimal Response After Prior Imatinib Treatment", 
        "overall_contact": {
            "email": "jlsteegmann@gmail.com", 
            "last_name": "Steegmann Juan Luis, Dr", 
            "phone": "91 520 23 16"
        }, 
        "overall_official": [
            {
                "affiliation": "PETHEMA Foundation", 
                "last_name": "Steegmann Juan Luis, Dr", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "PETHEMA Foundation", 
                "last_name": "Garc\u00eda Valent\u00edn, Dr", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Health Ministry", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the efficacy of dasatinib in terms of major molecular response rate at 6 months in patients with CP-CML who have achieved complete cytogenetic response without major molecular response after at least 18 months on Imatinib 400/600", 
            "measure": "Asses the efficacy", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802450"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the efficacy of dasatinib in terms of depth and kinetics of molecular response", 
                "measure": "Asses the efficacy", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To assess the relationship of dasatinib with the appearance of large granular lymphocytes and assess the relationship of LGL with efficacy and toxicity", 
                "measure": "Assess the relationship of dasatinib with the appearance of large granular lymphocytes", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "PETHEMA Foundation", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Dynamic Solutions", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Bristol-Myers Squibb", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "PETHEMA Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}